top of page

Biomarker Discovery Services

Precision medicine meets real-time breath analysis

Breath Analysis: The Next Frontier

Breath analysis
Breath sensors

Volatile Organic Compounds (VOCs) are gaseous molecules generated as by-products of the body's metabolic activities. With over 1,000 VOCs present in every breath, their accurate interpretation offers a robust and comprehensive assessment of the body's health status. Through the pioneering efforts of scientific and academic institutions worldwide, the utilisation of breath analysis in healthcare has evolved from a promising concept to a validated scientific method, posing to coexist with traditional blood, saliva, and urine analyses in the near future.

Today, the question is not whether breath analysis is a reliable method, but rather which technology is most suitable to meet our healthcare standards, and which diseases and applications to prioritize. built on the world's most advanced real-time gas analytics technology, powered by AI


From inception to completion, we cover every step of the biomarker discovery process.

Clinical Trial Planification

Biomarker Discovery

Assay Development & Validation



Like with our first found success in COVID-19, real-time breath analysis is a proven technique for non-invasive, immediate, and highly accurate diagnostics.   

Patient monitoring:

By enabling continuous monitoring of breath profiles, we can offer immediate insights into changes in health status. Detecting fluctuations in Volatile Organic Compounds (VOCs) in real-time facilitates proactive interventions and personalized treatment adjustments for patients.


Breath analysis has demonstrated remarkable accuracy in predicting the progression of numerous medical conditions. To further the proof, we are currently investigating its application in prevalent respiratory diseases such as COPD and asthma, aiming to forecast the probability of patients' suffering from exacerbations based on their breath profile. Such predictive insights could revolutionize respiratory care.

Therapy response prediction:

Certain VOCs are inherently unique to each individual, or group of individuals, allowing us to correlate specific VOC patterns with particular therapy responses. By analysing these patterns, we can stratify patients based on their likelihood of responding to a given therapy, enabling caregivers to tailor treatments accordingly. This application holds great promise for the development of novel precision drugs. Our recent studies have yielded highly encouraging results in our capacity of predicting the response of patients to a novel precision drug for the treatment of Cystic Fibrosis. 


Jose Alberto Lopez

José A. López Montemayor, MBA

CEO, co-founder

  • Grey LinkedIn Icon
Stanislas Grassin-Delyle

Prof. Stanislas Grassin-Delyle

CMO & CSO, co-founder

  • Grey LinkedIn Icon


bottom of page